Literature DB >> 21646441

Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment.

Jae Eun Ahn1, Elodie L Plan, Mats O Karlsson, Raymond Miller.   

Abstract

The purpose of this study was to describe longitudinal daily seizure count data with respect to the effects of time and pregabalin add-on therapy. Models were developed in a stepwise manner: base model, time effect model, and time and drug effect (final) model, using a negative binomial distribution with Markovian features. Mean daily seizure count (λ) was estimated to be 0.385 (relative standard error [RSE] 3.09%) and was further increased depending on the seizure count on the previous day. An overdispersion parameter (OVDP), representing extra-Poisson variation, was estimated to be 0.330 (RSE 11.7%). Interindividual variances on λ and OVDP were 84.7% and 210%, respectively. Over time, λ tended to increase exponentially with a rate constant of 0.272 year⁻¹ (RSE 26.8%). A mixture model was applied to classify responders/nonresponders to pregabalin treatment. Within the responders, λ decreased exponentially with respect to dose with a constant of 0.00108 mg⁻¹ (RSE 11.9%). The estimated responder rate was 66% (RSE 27.6%). Simulation-based diagnostics showed the model reasonably reproduced the characteristics of observed data. Highly variable daily seizure frequency was successfully characterized incorporating baseline characteristics, time effect, and the effect of pregabalin with classification of responders/nonresponders, all of which are necessary to adequately assess the efficacy of antiepileptic drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21646441     DOI: 10.1177/0091270011407193

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Does accounting for seizure frequency variability increase clinical trial power?

Authors:  Daniel M Goldenholz; Shira R Goldenholz; Robert Moss; Jacqueline French; Daniel Lowenstein; Ruben Kuzniecky; Sheryl Haut; Sabrina Cristofaro; Kamil Detyniecki; John Hixson; Philippa Karoly; Mark Cook; Alex Strashny; William H Theodore; Carl Pieper
Journal:  Epilepsy Res       Date:  2017-07-25       Impact factor: 3.045

2.  A big data approach to the development of mixed-effects models for seizure count data.

Authors:  Joseph J Tharayil; Sharon Chiang; Robert Moss; John M Stern; William H Theodore; Daniel M Goldenholz
Journal:  Epilepsia       Date:  2017-03-30       Impact factor: 5.864

3.  N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Authors:  Sherwin K B Sy; Lizanne de Kock; Andreas H Diacon; Cedric J Werely; Huiming Xia; Bernd Rosenkranz; Lize van der Merwe; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

4.  Natural variability in seizure frequency: Implications for trials and placebo.

Authors:  Juan Romero; Phil Larimer; Bernard Chang; Shira R Goldenholz; Daniel M Goldenholz
Journal:  Epilepsy Res       Date:  2020-03-06       Impact factor: 3.045

5.  Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex.

Authors:  François Pierre Combes; Guillaume Baneyx; Neva Coello; Penny Zhu; William Sallas; Hequn Yin; Jerry Nedelman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-10       Impact factor: 2.745

6.  Modeling and simulation of count data.

Authors:  E L Plan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-08-13

7.  New generalized poisson mixture model for bimodal count data with drug effect: An application to rodent brief-access taste aversion experiments.

Authors:  Y Sheng; J Soto; M Orlu Gul; M Cortina-Borja; C Tuleu; J F Standing
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-07-29

8.  Change in the Frequency of Seizure Attacks and Associated Factors Among Adult Epilepsy Patients at Amanuel Mental Specialized Hospital (AMSH): A Generalized Linear Mixed Model (GLMM).

Authors:  Temam Beshir Raru; Bisrat Misganaw Geremew; Koku Sisay Tamirat
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-04       Impact factor: 2.570

9.  Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.

Authors:  Rik Schoemaker; Janet R Wade; Armel Stockis
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.